Prognostic Factors of Long-term Response to Treatment With Pegylated Interferon Alfa-2a in Patients With HbeAg-negative Chronic Hepatitis B. (Perseas)

Trial Profile

Prognostic Factors of Long-term Response to Treatment With Pegylated Interferon Alfa-2a in Patients With HbeAg-negative Chronic Hepatitis B. (Perseas)

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 May 2015

At a glance

  • Drugs Peginterferon alfa-2a (Primary)
  • Indications Hepatitis B
  • Focus Therapeutic Use
  • Acronyms Perseas
  • Sponsors Roche
  • Most Recent Events

    • 15 Aug 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 15 Aug 2012 Actual end date changed from 1 Mar 2010 to 1 May 2009 as reported by ClinicalTrials.gov.
    • 15 Aug 2012 Planned end date changed from 1 Sep 2012 to 1 Apr 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top